Product Liability

  • May 20, 2008

    Wyeth Calls For End To Discovery In Prempro MDL

    Wyeth Pharmaceuticals Inc. has urged a federal judge to set a deadline for generic discovery in the multidistrict proceedings over its hormone pills, saying the speedy resolution of the litigation required an end to the drawn-out pretrial phase.

  • May 20, 2008

    Asarco, Montana Bury Hatchet Over Toxic Site

    After years of wrangling over environmental liabilities, Asarco LLC has reached a settlement with the state of Montana over a toxic site, marking the latest in a series of truces for the bankrupt mining and smelting company.

  • May 21, 2008

    Group Threatens Legal Action Over Nanotubes

    The International Center for Technology Assessment said Wednesday it planned to take legal and regulatory action over carbon nanotubes, citing a new study that suggests the asbestos-shaped cylinders could cause the same pathogenic behavior as asbestos.

  • May 20, 2008

    Hospitals Have Mandamus Relief: Texas High Court

    In a 6-3 opinion handed down Friday, the Supreme Court of Texas conditionally granted McAllen Medical Center's writ of mandamus, ruling that mandamus relief is available to hospitals when the purposes of the rules governing health care would otherwise be defeated.

  • May 20, 2008

    Automakers Balk At Federal-Mogul Injunction Bid

    A group of claimants led by DaimlerChrysler Corp., Volkswagen of America Inc. and Ford Motor Co. is seeking to stop the asbestos personal injury trust created by Federal-Mogul Corp.'s reorganization plan from succeeding in its recent injunction request, arguing that the trust is trying to “re-trade” on an earlier deal.

  • May 20, 2008

    Merck Settles With States Over Vioxx Marketing

    Merck & Co. has agreed to open up its checkbook again to resolve allegations related to its painkiller Vioxx, this time agreeing to pay $58 million to settle allegations that the company downplayed health risks in consumer advertisements.

  • May 20, 2008

    Mirapex Plaintiffs Add Punitive Damages To Claim

    The Minnesota plaintiffs in the Mirapex product liability litigation have taken advantage of a ruling that gave them the green light to demand punitive damages, filing an amended complaint in their ongoing case against several major drugmakers.

  • May 19, 2008

    Companies Fined For Water Contamination In Arizona

    Motorola Inc., Siemens Corp. and GlaxoSmithKline agreed on Monday to collectively pay a $500,000 penalty for accidentally releasing a dangerous contaminant into an Arizona public drinking water system.

  • May 19, 2008

    Mix-Up Leads To Acne Medication Recall

    Specialty pharmaceutical firm Medicis Pharmaceutical Corp. has voluntarily recalled two lots of its antibiotic acne medication Solodyn after discovering that one bottle in the lots contained another drug, Azasan.

  • May 19, 2008

    Judge Blasts Parties For Delay In Guidant MDL

    A dispute over how to carry out the terms of the master settlement agreement in the multidistrict litigation against Boston Scientific Corp. over Guidant's implantable defibrillators has led to the court faulting the parties for wasting time, generating unnecessary fees and a lack of coordination.

  • May 19, 2008

    FDA Stresses Dangers Of Transplant Drugs

    Federal regulators warned again Friday that organ-transplant drugs made by Roche Holding AG and Novartis AG cause miscarriages and birth defects when taken by pregnant women.

  • May 16, 2008

    Light Cigarettes Marketing Bill Heads To Senate

    A bill that would stop tobacco companies from using a ratings method for low-tar cigarettes that has been criticized for being confusing to consumers has passed a key congressional committee and will head to the U.S. Senate floor.

  • May 16, 2008

    FDA Shuts Down Unlicensed Cough Medicine Co.

    After three years of warnings for allegedly selling untested prescription cough and cold medicine, Scientific Laboratories Inc. has been shut down by the U.S. Food and Drug Administration.

  • May 16, 2008

    Exxon Unit Hit With $8M Verdict For Kidney Cancer

    A state court jury in San Francisco has awarded $8 million to a veteran employee of Exxon Mobil Corp. subsidiary SeaRiver Maritime Inc. who claimed he developed kidney cancer after being exposed to toxins on the job.

  • May 16, 2008

    Lead Paint Manufacturers Balk At $2.4B Price Tag

    Three companies that once manufactured lead paint are asking Rhode Island's highest court to overturn a jury verdict against them and to let them off the hook for the $2.4 billion cleanup the state is demanding.

  • May 19, 2008

    Biovail To Pay $24.6M Over Cardizem Marketing

    Biovail Corp.’s pharmaceutical subsidiary has agreed to shell out $24.6 million to resolve criminal charges brought by the U.S. Department of Justice related to Biovail's blood pressure drug Cardizem LA.

  • May 15, 2008

    Bayer Pulls Remaining Trasylol From U.S. Market

    Bayer AG has yanked the leftover stock of its blood-clotting drug Trasylol from the U.S. market amid increasing fears that the drug may cause kidney failure and increase the risk of death.

  • May 15, 2008

    Ford Recalls Over 600,000 Pickup Trucks

    Ford Motor Co., which has recalled millions of vehicles over the past decade to fix a cruise-control deactivation switch, is now recalling more than 600,000 Ford F-150 and Lincoln Mark LT pickup trucks due to a problem with their brake hoses.

  • May 15, 2008

    Baker Botts Picks Up Two Cos. In MTBE MDL

    Two defendants have substituted Baker Botts LLP for Howrey LLP in a multidistrict litigation that claims a slew of oil companies allowed a gasoline additive to leak into groundwater used by 153 public water providers in 17 states.

  • May 14, 2008

    Fen-Phen Lawyers' Fraud Trial Gets Under Way

    Opening arguments began Tuesday in the criminal trial of three lawyers who stand accused of keeping millions of dollars meant for plaintiffs in a class action settlement over the diet drug fen-phen, with the prosecution and the defense reportedly trading barbs over whether the attorneys were entitled to the money.